Skip NavigationSkip to Content
Return Return to Search Results

Schiff base-Poloxamer P85 combination demonstrates chemotherapeutic effect on prostate cancer cells in vitro.

  1. Author:
    Demirci, Selami
    Dogan, Aysegül
    Türkmen, Nese Basak
    Telci, Dilek
    Rizvanov, Albert A
    Sahin, Fikrettin

  2. Author Address

    Department of Genetics and Bioengineering, Faculty of Engineering and Architecture, Yeditepe University, Istanbul, Turkey; National Heart, Lung, and Blood Institute (NHLBI), NIH, Bethesda, MD, United States., Department of Genetics and Bioengineering, Faculty of Engineering and Architecture, Yeditepe University, Istanbul, Turkey; National Cancer Institute (NCI), CDBL, NIH, Frederick, MD, United States. Electronic address: aguldgn@gmail.com., Department of Pharmaceutical Toxicology, University of Inonu, Malatya, Turkey., Department of Genetics and Bioengineering, Faculty of Engineering and Architecture, Yeditepe University, Istanbul, Turkey., Kazan Federal University, Kazan, Russia.,
    1. Year: 2017
    2. Date: Feb
    3. Epub Date: 2016 Dec 22
  2. Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
    1. 86
    2. Pages: 492-501
  4. Type of Article: Article
  5. Article Number: 492-501
  6. ISSN: 0753-3322
  1. Abstract:

    Prostate cancer is a multistep and complicated cancer type that is regulated by androgens at the cellular level and remains the second commonest cause of death among men. Discovery and development of novel chemotherapeutic agents enabling rapid tumor cell death with minimal toxic effects to healthy tissues might greatly improve the safety of chemotherapy. The present study evaluates the anti-cancer activity of a novel heterodinuclear copper(II)Mn(II) complex (Schiff base) in combination with poly(ethylene oxide) and poly(propylene oxide) block copolymer (Pluronic) P85. We used assays for cell proliferation, apoptosis, cell migration and invasion, DNA binding and cleavage to elucidate the molecular mechanisms of action, in addition to the anti-inflammatory potency of the new combination. The combined treatment of Schiff base and P85 lead to a remarkable anti-cancer effect on prostate cancer cell lines. Cell proliferation was inhibited in Schiff base-P85 treatment. The activity of this formulation is on DNA binding and cleavage and prevents inflammation in in vitro conditions. This is the first study presenting the anti-cancer activity of the present Schiff base derivative and its combination with P85 to treat prostate cancer in vitro. Copyright © 2016 Elsevier Masson SAS. All rights reserved.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1016/j.biopha.2016.11.101
  3. PMID: 28012929
  4. View record in Web of Science®
  5. WOS: 000395523800061

Library Notes

NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel